Acute Myeloid Leukemia
|
|
- Christine Wilkinson
- 5 years ago
- Views:
Transcription
1 Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope
2 Acute Myeloid Leukemia Gene mutations Ç ç
3 In 2015, approximately 20,000 new cases of AML and 10,000 disease-related deaths occurred in the United States alone The median age at diagnosis is 67 years and the incidence of the disease increases with age AML comprises several distinct entities that are molecularly heterogeneous. Molecular heterogeneity is clinically relevant, is associated with outcome and has been used for treatment selection Despite molecular risk-based approaches, however, only approx. 40% of younger (<60 year/old) and 10% of older (>60 years) achieved cure when treated with currently available chemotherapies Allogeneic HCT may improve cure rate, but the long-term success may be somewhat limited by transplant-related toxicity and death
4 Age, Survival, and Treatment Era in AML 1. Kantarjian H et al. Cancer. 2010;21:
5 Principle of AML Treatment for Younger Patients Remission consolidation D i a g n o s i s Remission induction 7+3 x 1-2 courses CR Favorable Clinical Trials Intermediate Adverse High-dose Ara-C Allo HCT Relapse No CR Salvage chemotherapy
6 Principle of AML Treatment for Older Patients Remission consolidation D i a g n o s i s Low intensity 7+3 x 1-2 courses CR Low intensity Clinical Trials Modified HiDAC RIC Allo HCT Relapse No CR Clinical Trials Best Supportive Care
7 Treatment questions Is a high risk AML? Chemotherapy dosage? MRD status? Type of HCT? Molecular targeting therapeutics What? How? When?
8 Current Approaches to AML Based on prognostic and predictive factors: Age Chemotherapy Antecedent hematologic disorder Risk Factors in AML Comorbid conditions Cytogenetics Molecular markers Minimal residual disease 1. NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. Version Grimwade D, Hills RK. Hematology Am Soc Hematol Educ Program. 2009: Estey EH. Am J Hematol. 2013;88:
9 Frequency Distribution of Major Chromosome Abnormalities among 4246 Adults with AML not Therapy-related 42% - normal karyotype 20% - other aberrations 5% - t(8;21) 12% - complex karyotype CALGB 8461, % - inv(3)/t(3;3) 0.5% - t(6;9) 1.7% - t(9;11) 2.4% - t(11q23) 9% - t(15;17) 6% - inv(16)
10 Impact of cytogenetics F I A David Grimwade et al. Blood 2010;116: by American Society of Hematology
11 *Reported in order of discovery as prognostic (separately for mutations and expression) Green ( ) ** First molecular prognostic marker in CN-AML *** Recommended for study in CN-AML by WHO 2008, ELN 2009, NCCN 2011 Prognostic Single-gene Markers in Primary Adult CN-AML Gene Symbol Gene Location Prognostic Impact Frequency MLL-PTD** (1998) 11q23 Adverse Neutral 5-10% FLT3-ITD*** (1999) 13q12 Adverse 30-35% FLT3-TKD (2002) 13q12? Adverse ~10% CEBPA mutations*** (2002) 19q13.1 Favorable 10-20% NPM1 mutations*** (2005) 5q35 +/-Favorable 55-65% WT1 mutations (2007) 11p13 Adverse 6-12% IDH mutations (IDH1 & IDH2) (2009) 2q33.3 & 15q26.1 +/- Adverse 25-35% RUNX1 mutations (2009) 21q22.12 Adverse 8-16% TET2 mutations (2010) 4q24 +/- Adverse 18-30% ASXL1 mutations (2010) 20q11.21 Adverse 4-16% DNMT3A mutations (2011) 2p23.3 Adverse ~35%
12 ELN Clinical Practice Guidelines: New Recommended Standardized Reporting for Correlation of Cytogenetic & Molecular Genetic Data with Clinical Data in AML* Genetic Group Subsets Favorable Intermediate-I Intermediate-II Adverse t(8;21)(q22;q22); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated NPM1 without FLT3-ITD (normal karyotype) Mutated CEBPA (normal karyotype) Mutated NPM1 and FLT3-ITD (normal karyotype) Wild-type NPM1 and FLT3-ITD (normal karyotype) Wild-type NPM1 without FLT3-ITD (normal karyotype) t(9;11)(p22;q23); MLLT3-MLL; Cytogenetic abnormalities not classified as favorable or adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 t(6;9)(p23;q34); DEK-NUP214 t(v;11q23); MLL rearranged 5 or del(5q); 7; abn(17p); complex karyotype ( 3) 2 *International expert panel recommendations on behalf of ELN (Blood 115:453-74, Epub 2009 Oct 30)
13 Overall Survival ELN Genetic Groups Associate with Overall Survival among Younger and Older Patients 1.0 P <.001 < 60 yrs 1.0 P < yrs 0.8 Favorable (n=339) 0.8 Favorable (n=145) Intermediate-II (n=156) Intermediate-I (n=144) Intermediate-II (n=222) Intermediate-I (n=136) Adverse (n=179) Years Adverse (n=229) Years
14 Morphology Molecular characterization Next Generation Sequencing Cytogenetics Immunophenotype
15 The Cancer Genome Atlas Research Network. N Engl J Med 2013;368:
16 Döhner H et al. N Engl J Med 2015;373: Mutations Themes in AML
17 Unsupervised RNA and mirna Expression Patterns The Cancer Genome Atlas Research Network. N Engl J Med 2013;368:
18 Unsupervised Analysis of DNA Methylation The Cancer Genome Atlas Research Network. N Engl J Med 2013;368:
19 Integrated Genetic-Epigenetic Molecular (GEM) Score Mutational Analysis Methylome Analysis Gene Expression Analysis Identification of unique Differentially Methylated Regions (DMRs) associated with each prognostic gene mutation Identification of the DMRs whose methylation levels impact on outcome Identification of genes whose both promoter DMRs and expression impact on outcome CALGB 8525,8923,9420,9720,10201 Marcucci, et al, JCO 2013
20 OS of Older Patients With CN AML: Impact of Seven Genes GEM Score 1 Gene a CD34 Chromosome Location 1q32 RHOC 1p13.1 SCRN1 F2RL1 7p14.3-p14.1 5q13 FAM92A1 8q22.1 MIR155HG 21q12.3 VWA8 13q14.11 Outcome P-value No. 0-1 of 2-3 genes CR < % 80% 54% 25% a Genes are ordered according to decreasing gene expression HRs. 1. Marcucci G et al. J Clin Oncol. 2014;32:
21 Chemotherapy : What is the best dose? The standard combination is the 7+3, continuous infusion of cytarabine at the dosage of 100 or 200 mg/m 2 per day on days 1 to 7 Anthracycline ( daunorubicin or idarubicin on days 1 to 3) CR is expected in 60-85% younger and 40-60% older High-dose cytarabine-based regimens achieve high CR rates, but it remains to be determined if higher than standard dose cytarabine without worsening toxicity
22 Randomized Trials of Escalated Daunorubicin E1900 trial: 90mg/m 2 vs 45mg/m 2 in adults <60 years (n=657) Fernandez HF et al. NEJM, 2009;361: CR 70% vs 57%/ OS 38% vs 23% -benefit in <50 s, intermediate cytogenetics HOVON trial: 90mg/m 2 vs 45/m 2 in adults >60 years (n=813) Lowenberg B et al. NEJM, 2009;361: CR: 64% vs 54%/ OS: no difference - benefit in yrs/ trend in CBF subgroup (35% vs 23%) Korean Trial: 90mg/m 2 vs 45mg/m 2 in adults <60 years (n=383) Lee J-H et al. Blood, 2011;118: OS: 51% vs 34% - benefit due to intermediate risk
23 AML17: DA60 vs DA90 Censored at Transplant
24 Probability of DFS According to Age and Consolidation Dosage of Cytarabine All Younger Older Mayer RJ et al. N Engl J Med 1994;331:
25 Tyrosine Kinase Inhibitors
26 CALGB 10603: Prospective Phase III, double-blinded randomized study of induction and consolidation +/- Midostaurin (PKC412) in newly diagnosed patients < 60 years old with FLT3 mutated AML 26 R E G I S T E R FLT3 ITD or TKD R A N D O M I Z E DNR ARA-C PKC412 DNR ARA-C PLACEBO CR CR HiDAC PKC412 HiDAC PLACEBO X 4 X 4 PKC412 MAINTENANCE 12 months PLACEBO MAINTENANCE 12 months Not on STUDY: FLT3 WILD TYPE Study drug is given on Days 8-21 after each course of chemotherapy, and Days 1-28 of each 28 day Maintenance cycle.
27 27 Overall Survival without transplant censoring (p=0.0076) censored at the time of transplant (p=0.05)
28 Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial CR 59%vs 60% (P=.7) median EFS 9.2 vs 20.5 months (p=0.013) 3-year EFS 22% vs 40% median RFS 23 months vs not reached after corresponding to a 3-year RFS of 38% vs 56%, (p=0.017) median OS not reached in either arm; 3-year OS 56% vs 63% (p=0.382). In FLT3-ITD positive patients, no difference in EFS.
29 Rationale for Using TKI in CBF AML CBF AML: a favorable cytogenetic subset with t(8;21) [RUNX1/RUNX1T1] or inv(16)[cbfb/myh11] KIT mutations, which result in aberrant tyrosine kinase activity and leukemia growth, are present in ~ 25-30% of CBF AML and associate with worse outcomes Higher expression of wild-type KIT is found in CBF AML and may associate with worse outcome Therefore, novel therapeutic approaches targeting aberrantly activated KIT are being tested
30 CALGB A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib in Newly Diagnosed CBF AML P R E - R E G I S T R A T I O N S C R E E N I N G R E G I S T R A T I O N Ara-C Daunorubicin + Dasatinib X 1-2 courses Remission induction CR High-dose Ara-C + Dasatinib X 4 cycles Remission consolidation Dasatinib X 12 months Maintenance
31 Clinical Outcomes Median Follow-up N= months (range ) 30-day Survival Rate 97% CR Rate 90% 24-month DFS Rate 71% (95%CI: 58-88) 24-month OS Rate 85% (95%CI: 76-94)
32 C10801vs C9621 & C19808 CALGB CALGB 9621 & (YOUNGER ONLY) Younger C1980-Younger Older C9621-Younger Younger C1980-Younger Older C9621-Younger
33 CD33 Antibodies
34 Gemtuzumab Ozogomycin (Mylotarg) ALFA Newly-diagnosed Age ± GO GO dose 3 mg/m 2 Median OS improved MRC AML16 2 Untreated, older AML Chemo ± GO GO dose 3 mg/m 2 OS improved Meta-analysis 3 Five RCTs (3,325 patients) No improvement in CR rate OS rate improved Best results in CBF AML Favorable-Risk AML 1. Castaigne S et al. Lancet. 2012;379: Burnett AK et al. Br J Haematol. 2012;158: Hills RK et al. Lancet Oncol. 2014;15:
35 Targeting CD33 Antibody-drug conjugate SGN-CD33A AML Byte CAR-T cells Clinical trials: single agents with 7+3 with hypomethylating with allohct
36 Hypomethylating Agents
37 Hypomethylating agents in older patients with AML OS in Patients With AML-MRC: AZA vs CCR 1 Decitabine vs Total TC in AML 65 Years 2 1. Dombret H et al. Blood. 2015;126: Kantarjian HM et al. J Clin Oncol. 2012;30:
38 DNMT3A Mutations As Response Predictors for Hypomethylating Agents in AML 46 mostly older AML patients (median age, 74 years) treated with 20 mg/m 2 decitabine on a 10-day schedule in phase I/II trials. CR rate of entire cohort: 41% DNMT3A mutations found in 17% of patients DNMT3A mutations were associated with P=.05 a better response to decitabine (P=.05) CR rate 100% 80% 60% 40% 20% 0% DNMT3Amutated n=8 CR rate P=.05 75% 34% DNMT3Awild-type n=38 DNMT3Awild-type n=38 Metzeler et al. Leukemia, 2012
39 Approaches to Relapsed or Primary Refractory AML 20-30% of AML patients may be refractory to initial remission induction chemotherapy Disease relapse occurs within 3 years after diagnosis for most patients with AML A short duration of remission (i.e., <6 months), adverse genetic factors, prior allosct, older age, and poor general health status are the main negative determinants of outcome after relapse There have been few controlled trials providing data regarding the best salvage regimen for AML patients with refractory or relapsed disease Commonly used intensive salvage regimens are designed to achieve a CR and proceed to allohsct in order to maximize the chances of durable remission
40 Minimal Residual Disease Method Target Sensitivity Strengths and Weaknesses Flow cytometry Leukemia-associated aberrant immunophenotype 1/10,000 (0.01%) Applicable to most AML cases RQ-PCR Fusion transcripts, gene mutations, overexpressed genes 1/1,000,000 (0.0001%) Highly sensitive A B C D (A) after induction cycle 1, (B) after cycle 2, (C) after consolidation (D) after cycle 2, good risk; (E) after cycle 2, intermediate risk; (F) after cycle 2, poor risk. Flow 1. Ravandi F, Jorgensen JL. J Natl Compr Canc Netw. 2012;10: Terwijn M et al. J Clin Oncol. 2013;31: Krönke J et al. J Clin Oncol. 2011;29: E F
41 All pts Minimal Residual Disease in Blood after the Second Cycle of Chemotherapy and Clinical Outcomes in NPM1 positive patients Ivey A et al. N Engl J Med 2016;374: w/o FLT3-ITD w FLT3-ITD w/o DNMT3A w DNMT3A
42 AML:New Drugs Agent Mechanism of action Comments Clinical trials Multicenter randomized phase III trial in combination with cytarabine did not Vosaroxin meet primary end NCT ; Cytotoxic; DNAintercalating agent point, but NCT ; demonstrated NCT improved outcomes in older patients. Lower intensity trials ongoing. CPX-351 Cytotoxic; liposomal formulation of cytarabine and daunorubicin in 5:1 molar ratio Cytotoxic; orally Sapacitabine bioavailable novel nucleoside analog SGI-110 Volasertib Cytotoxic; longer acting hypomethylating agent Randomized trial of CPX-351 versus demonstrated NCT ; improved outcomes in NCT patients with secondary AML. Single-agent sapacitabine had outcomes similar to LDAC, but sequential combination study with NCT decitabine showed promising results. A randomized study of this approach is ongoing. Single-agent activity in AML and myelodysplastic syndrome seems promising. A randomized study versus conventional care is ongoing, as are combination studies. A phase II study of volasertib combined Small-molecule inhibitor with LDAC of Polo-like kinase demonstrated improved outcomes over LDAC. A NCT ; NCT ; NCT NCT ; NCT AG-221 AG-120 ABT-199 Sorafenib Small-molecule inhibitor of isocitrate dehydrogenase (IDH)-2 enzyme Small-molecule inhibitor of IDH-1 enzyme Small-molecule BH3 mimetic, inhibitor of BCL-2 Small-molecule multikinase inhibitor with activity against mutant FLT3 (FLT3-ITD) in AML Midostaurin Small-molecule multikinase inhibitor Single-agent studies have reported significant activity in patients with IDH2- mutated AML. Combination studies with conventional chemotherapy have been planned. Single-agent study has demonstrated activity in patients with IDH1- mutated AML. Combination studies are planned. NCT ; NCT NCT Single-agent ABT-199 demonstrated a signal of response in patients with AML, particularly in NCT ; patients with IDH NCT mutations. Combination studies are now underway. Following several single-arm studies, a phase III randomized study of with or without sorafenib demonstrated improved outcomes (but not improved OS) with sorafenib in younger patients with AML. A randomized study in older patients did not show a benefit. Lower intensity therapy such as hypomethylating agents are being studied in combination with sorafenib. Results from a large phase III randomized NCT ; NCT NCT Small-molecule multikinase inhibitor with Quizartinib potent activity against FLT3-ITD Small-molecule kinase inhibitor with activity Crenolanib against mutant FLT3 (both FLT3-ITD and FLT3-D835) ASP2215 FLX925 SGN-33a AMG-330 Small molecule both FLT3 and AXL kinases Small-molecule inhibitor of both FLT3 kinase and CDK4/6 Monoclonal antibodydrug conjugate directed at CD33, carrying a pyrrolobenzodiazepine dimer (toxin) Monoclonal bispecific antibody directed at CD33 and CD3 Single-agent dosefinding studies have demonstrated efficacy, but DLT is QT prolongation. Lower doses of quizartinib have demonstrated similar activity but less toxicity. These are now being studied in combination studies. Single-agent studies have demonstrated activity in heavily pretreated patients; combination studies are now being conducted Single-agent studies are just underway, with preliminary data anticipated. Single-agent studies are just underway, with preliminary data anticipated. Single-agent and combination studies are underway in several clinical settings. Preliminary experience is positive, demonstrating good safety profile and efficacy in clearing bone marrow blasts. Single-agent studies are just getting underway. NCT ; NCT ; NCT ; NCT ; NCT NCT ; NCT ; NCT NCT NCT ; NCT NCT
43 IDH Mutations As a Target in AML IDH is a critical enzyme of the citric acid cycle IDH mutations occur in a spectrum of solid and hematologic tumors IDH2 mutations: 9-13% of AML and 3-6% of MDS IDH1 mutations: 6-10% of AML and 3% of MDS IDH1/2 mutations confer a gain-of-function Increased DNA methylation Impaired cellular differentiation
44 Normal and Aberrant IDH Activities
45 Clinical Impact of Distinct IDH Mutations in AML 1,2 Cytogenic Classification Mutations Overall Risk Profile Favorable Any FLT3/ITD negative Mutant NPM1 and IDH1 or IDH2 Favorable FLT3/ITD negative Wild-type ASXL1, MLL- PTD, PHF6, and TET2 Normal karyotype or intermediaterisk cytogenetic lesions FLT3/ITD negative or positive FLT3/ITD positive FLT3/ITD negative Mutant CEBPA Wild-type MLL-PTD, TET2, and DNMT3A and trisomy 8 negative Mutant TET2, MLL-PTD, ASXL1, or PHF6 Intermediate FLT3/ITD positive Mutant TET2, MLL-PTD, DNMT3A, or trisomy 8, without mutant CEBPA Unfavorable Unfavorable Any 1. Marcucci et al. J Clin Oncol. 2010;28: Patel JP et al. N Engl J Med. 2012;366:
46 Best Overall Response of AG221 by Cumulative Daily Dose 1,a 75 mg (n = 9) 100 mg (n = 14) 150 mg (n = 22) Total (n = 45 efficacy evaluable) CR CRp Marrow CR CRi 1 1 ORR 4/9 6/14 5/22 15/45 (33%) Marrow CR = 5% blasts in BM; no hematological recovery. a Includes patients with a day-28 response assessment as of October 1, Excludes 12 ongoing patients with day 28 not yet available and 16 patients off study without a day-28 assessment. 1. Stein EH et al. ASH Abstract 115.
47 Ongoing Trials and Future Directions AG-120 (orally administered): phase 1 evaluation in subjects with advanced hematologic malignancies with an IDH mutation AG-221 and AG120 tested in combination with chemotherapy AG-221 and AG120 tested in combination with hypomethylating agents
48 Targeting Anti-Apoptotic Mechanisms
49 Background: MOA of Venetoclax (ABT-199/GDC-0199) 1 Pro-apoptotic Proteins (BAX, BAK) An Increase in Bcl-2 Expression Allows the Cancer Cell to Survive Anti-apoptotic Proteins (Bcl-2) 2 Venetoclax Binds to and Inhibits Overexpressed Bcl-2 Venetoclax BH3-only BAK BAX Bcl-2 Bcl-2 3 Apoptosome APAF-1 Cytochrome C Apoptosis is Initiated Active Caspase Procaspase Mitochondria Mitochondria Mitochondria 1. Konopleva M et al. ASH Abstract 118.
50 Overall Activity 1 Response N = 32 (%) Objective response (CR + CRi) 6 (19) CR 2 (6) CRi 4 (13) Response in Patients With IDH Mutations N = 11 (%) Objective response (CR + CRi) 4 (36) CR 2 (18) CRi 2 (18) 1. Konopleva M et al. ASH Abstract 118.
51 Venetoclax/Bcl-2 Inhibition: Ongoing Trials and Future Directions Combination with hypomethylating agents Combination with chemotherapy Combination with IDH inhibitors
52 Younger AML Patients CBF ELN Favorable ELN Intermediate I &II ELN Adverse KIT mutations IDH mutations FLT3 mutations 7+3 Clinical Trials (e.g., 7+3/ molecular therapeutics) 7+3 Clinical Trials (e.g., 7+3/ molecular therapeutics) 7+3 CR CR CR CR CR MRD MRD Clinical Trials (e.g., HiDAC and/or molecular therapeutics) Clinical Trials (e.g., HiDAC and/or molecular therapeutics) Neg Neg HiDAC allohsct allohsct Clinical Trials allohsct
53 Older Fit AML Patients CBF ELN Favorable ELN Intermediate I &II ELN Adverse KIT mutations IDH mutations FLT3 mutations 7+3 Clinical Trials (e.g., 7+3/ molecular therapeutics) 7+3 Clinical Trials 7+3 CR CR CR CR CR MRD MRD Modified HiDAC Clinical Trials (e.g., molecular therapeutics) allohsct Clinical Trials (e.g., IDAC and/or molecular therapeutics) Neg allohsct Clinical Trials allohsct
54 Older AML Patients Unfit or Unwilling to undergo intensive chemotherapy ELN Favorable (not CBF) ELN Intermediate I &II ELN Adverse IDH mutations FLT3 mutations Clinical Trials with (molecularly targeted therapeutics) OR HMAs BSC LDAC
55 Conclusions Exciting time in the treatment of AML because of novel molecular targets and new drugs and new transplant modalities that may lead to implementation of truly personalized therapies Challenge is how to best incorporate into clinical practice: Novel predictive biomarkers New drugs Treatment for MRD Prognostic risk assessment given the emrging predictive biomarkers and molecularly targeting agents
How the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationDisclosures. Clinical Advances in AML and MDS. Current Approaches to AML is based on prognostic and predictive factors:
Clinical Advances in AML and MDS Disclosures Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia esearch Chair, Dept. Hematologic Malignancies Translational Science City of Hope I have nothing
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationNovel Induction and Targeted Strategies in Acute Myeloid Leukemia
Novel Induction and Targeted Strategies in Acute Myeloid Leukemia Eytan M. Stein, MD Leukemia Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Current Paradigms
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationFLT-3 inhibitors in AML
FLT-3 inhibitors in AML Jorge Sierra Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona Rome, September 24, 2017 Disclosures Advisory board: Pfizer, NovarHs, Jazz, Celgene, SeaIle
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationAcute Myeloid Leukemia
Average annual rate per 100,000 Acute Myeloid Leukemia Guillermo Garcia-Manero Professor Department of Leukemia MD Anderson Cancer Center Putting the Problem into Perspective All other sites (~1,445,000)
More informationAcute Leukemia. Sebastian Giebel. Geneva 03/04/
Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012 www.ebmt.org Acute leukemias: EBMT survey 2 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant 2009 3 Acute leukemias: INCIDENCE
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationAcute Myeloid Leukemia: State of the Art in 2018
Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC Treatment Paradigm of Adults with AML Fit
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationClinical Overview on Measurable Residual Disease (MRD) in Acute Myeloid Leukemia(AML)
Clinical Overview on Measurable Residual Disease (MRD) in Acute Myeloid Leukemia(AML) Konstanze Döhner Department of Internal Medicine III, University Hospital of Ulm, Ulm Germany DISCLOSURES OF COMMERCIAL
More informationAcute myeloid leukemia: a comprehensive review and 2016 update
OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More information39% Treated. 61% Untreated. 33% UnRx. 45% UnRx. 59% UnRx. 80% UnRx
AML in the Elderly สน น ว ส ทธ ศ กด ช ย งานประช มว ชาการกลางป สมาคมโลห ตว ทยาแห งประเทศไทย คร งท 53 25-26 ต ลาคม 2561 ณ โรงแรมเลอ เมอร เด ยน เช ยงใหม จ งหว ดเช ยงใหม 33% UnRx 45% UnRx 59% UnRx 80% UnRx
More informationFrontline Induc.on Therapy in 2017 Alan K Burne+
Frontline Induc.on Therapy in 2017 Alan K Burne+ Ravenna, October 2017 Standard of Care Induc5on: 7+3 Ara-C / Daunorubicin Consolida5on: High Dose Ara-C (3g doses) Total of 4 courses. Myeloabla5ve allogral
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationTrapianto allogenico convenzionale
Il trapianto nella leucemia acuta mieloide a rischio intermedio Trapianto allogenico convenzionale Trapianto allogenico nelle Leucemie Acute Mieloidi in I RC D. Pastore Ematologia con Trapianto-Bari Domenico
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationThe Evolving Treatment Landscape in AML
The Evolving Treatment Landscape in AML Elias Jabbour, MD Associate Professor Section Chief, Acute Lymphocytic Leukemia Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More information«Adverse Prognosis» Acute Myeloid Leukemia
23. Fortbildungskurs Lausanne, 11.11.2017 «Adverse Prognosis» Acute Myeloid Leukemia Markus G. Manz Zentrum für Hämatologie und Onkologie UniversitätsSpital Zürich Content AML Update on current definition
More informationACUTE LEUKEMIA. Zwi N. Berneman University of Antwerp & Antwerp University Hospital. 16th Post-ASH Meeting Zaventem, 10 January 2014
ACUTE LEUKEMIA Zwi N. Berneman University of Antwerp & Antwerp University Hospital 16th Post-ASH Meeting Zaventem, 10 January 2014 ACUTE MYELOID LEUKEMIA HIGH-RISK AML Clinically and biologically distinct
More informationMRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationCARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital
CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationSubset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD. The University of Chicago
Subset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD The University of Chicago Disclosure Information 23 rd Annual Developmental Therapeutics Symposium
More informationWednesday, November 30, 2011 University of Michigan
Wednesday, November 30, 2011 University of Michigan Presenter Gary J. Schiller, MD, FACP Professor, Department of Medicine, Hematology/Oncology Director, Hematological Malignancies/Stem Cell Transplantation
More informationMeet-the-Expert: AML Treating older patients with AML
Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationUpdate on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationChanging AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Co-Moderators: Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society Mike
More informationMeasurable/Minimal Residual Disease in Patients with Acute Myeloid Leukemia Undergoing Transplantation
Measurable/Minimal Residual Disease in Patients with Acute Myeloid Leukemia Undergoing Transplantation June 9, 2018 Dave Sanford The Leukemia/Bone Marrow Transplant Program of British Columbia Disclosures
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationEmerging Therapeutics in Hematologic Malignancies
Emerging Therapeutics in Hematologic Malignancies Brian A. Jonas, MD, PhD Assistant Professor of Medicine UC Davis Comprehensive Cancer Center September 26, 2015 16th Annual Advances in Oncology 2015 September
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance
More informationUpdates in the Management of Acute Myeloid Leukemia
Updates in the Management of Acute Myeloid Leukemia Lydia Benitez, harmd, BCO 2017 TOA Conference I have no conflicts of interest with relation to the content of this presentation 4 Objectives Describe
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationLearning Objectives. Case A: Presentation. Case A Question Not included in Activity Survey. Acute Leukemia: Diagnosis and Prognosis
Learning Objectives Improve awareness of FDA-approved agents and/or therapies under development for the treatment of AML and ALL Incorporate FDA-approved agents and therapies under development into treatment
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationNew and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)
Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber
More informationAcute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far
Acute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far Martin S. Tallman, M.D. Chief, Leukemia Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationTherapeutic landscape in AML
Therapeutic landscape in AML Andrew Wei 1955: From the sea to Ara-C Cryptotethya crypta Werner Bergman Robert Feeney Bergmann W. & Burke D. C. 1955. Marine products. The nucleosides of sponges. 3: Spongothymidine
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationHighlights in acute leukemia
CONGRESS HIGHLIGHTS 28 Highlights in acute leukemia T. Feys, MSc, MBA SPECIAL EDITION There has been a long period of time without any new acute myeloid leukemia (AML) treatments. However, the tide has
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationAcute Myeloid Leukemia
The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. From the Department of
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More information2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA
2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA Adriano Venditti Ematologia Universita Tor Vergata, Roma Current Treatment Results in AML AGE, y CR%
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationHighlights in acute myeloid leukemia (AML): what is going to change?
29 Highlights in acute myeloid leukemia (AML): what is going to change? C. Graux, MD, PhD SUMMARY The decision making process in AML integrates clinical features, an increasing amount of genetic information
More informationFACULTY TRAINING TRANSCRIPT
FACULTY TRAINING TRANSCRIPT PROGRAM CURRICULUM REVIEWED BY: B. DOUGLAS SMITH, MD Professor of Oncology Johns Hopkins University, School of Medicine Baltimore, MD JONATHAN WEBSTER, MD Instructor of Oncology
More informationContinuing medical education activity in American Journal of Hematology
Continuing medical education activity in American Journal of Hematology CME Editor: Ayalew Tefferi, MD CME Author: Elihu H. Estey, MD CME Information: Acute myeloid leukemia: 2013 update on risk-stratification
More informationAcute Leukemia From Precision Medicine to ImmunoRx
Acute Leukemia From Precision Medicine to ImmunoRx Hagop M. Kantarjian, MD Professor and Chair, Department of Leukemia Samsung Distinguished Leukemia Chair in Cancer Medicine The University of Texas MD
More informationWHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationUpdates in Treatment Strategies for Acute Leukemia. Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016
Updates in Treatment Strategies for Acute Leukemia Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016 What is happening to standard of care in 2017? AML treatment
More informationUpdate on Optimal Management of Acute Myeloid Leukemia
Update on Optimal Management of Acute Myeloid Leukemia Fuad El Rassi, Emory University Martha Arellano, Emory University Journal Title: Clinical Medicine Insights: Oncology Volume: Volume 7 Publisher:
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationANCO Hematological Malignancies Update: The year in review. Midostaurin Vyxeos Gemtuzumab ozogamicin Enasidenib. The year in preview
ANCO Hematological Malignancies Update: Gabriel Mannis, MD Assistant Professor, and Marrow Co-Director, Cancer Immunotherapy Clinic Acute Leukemia Sacramento, CA June 16, 2018 OVERVIEW Overview The year
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More information